Here is our list of the 11 best cancer stocks to buy right now.

Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.

The Cleveland Clinic's Nathan Pennell, M.D., Ph.D., is switching to the Big Pharma realm to head up hematology and oncology ...

Bristol-Myers Squibb Company is pushing the boundaries with its latest clinical study on Deucravacitinib. The drug targets moderate to severe systemic lupus erythematosus (SLE). Employing a ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

Bristol-Myers Squibb Company announced a significant update in their Sjögren’s Syndrome study. The Phase 3 study tests ...

At the same time, more than half of the US-listed stocks covered by Morningstar that reported earnings as of Aug. 11 beat ...

In July 2025, Merck Sharp & Dohme LLC announced a substudy is to assess the efficacy and safety of ifinatamab deruxtecan ...

DelveInsight's GnRH Receptor Antagonists Market Size, Target Population, Competitive Landscape & Market Forecast report ...

Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly ...

Summit Therapeutics, which has consistently been communicating quarterly results through investor calls in the past few years ...